EBV CAR-T Cells for Nasopharyngeal Carcinoma

• 1)Voluntarily sign written informed consent;
• 2)Age ≥18, ≤75 years old, male and female;
• 3 )Estimated survival ≥ 3 months;
• 4. ECOG physical fitness score was 0-2;
• 5. EBV positive nasopharyngeal carcinoma was diagnosed;
• 6. Positive target detection;
• 7. At least one measurable lesion according to RECIST V1.1 solid tumor evaluation criteria;
• 8. Patients with recurrent/metastatic nasopharyngeal carcinoma who had previously failed second-line or higher systemic therapy;
• 9. Monopheresis or venous blood collection venous access can be established, and there are no other contraindications for blood cell separation;
• 10. Full organ and bone marrow function,
• 11. Toxicity and side effects left by previous anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, etc.) ≤ grade 1 (CTCAE 5.0);
• 12. Fertile subjects (male or female) must use effective medical contraception during the study period and for 6 months after the end of administration. In female subjects of reproductive age, a negative pregnancy test should be performed within 72 h prior to the first dose.

Exclusion Criteria:

• 1. There are active CNS metastases (except those stabilized by treatment);
• 2)HIV positive, HBsAg positive, HBV DNA copy number positive (quantitative test ≥1000cps/ mL), HCV antibody positive and HCV RNA positive;
• 3. Those with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation;
• 4. subjects with severe autoimmune diseases and long-term use of immunosuppressants;
• 5. Within 14 days prior to enrollment, there were active or uncontrollable infections requiring systemic treatment;
• 6. Any unstable systemic disease
• 7. Complicated with lung, brain, kidney and other important organ dysfunction;
• 8. Subjects have undergone major surgery or trauma in the 4 weeks prior to receiving cell therapy, or are expected to undergo major surgery during the study period;
• 9. Subjects received their last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, or immunotherapy) within 4 weeks prior to receiving cell therapy;
• 10. The subject currently has or has had other malignancies that cannot be cured within 3 years, except cervical carcinoma in situ or basal cell carcinoma of the skin, and other malignancies with disease-free survival of more than 5 years;
• 11. T cells modified with chimeric antigen receptor (CAR T, TCR-T) within six months;
• 12. Combined graft versus host disease (GVHD);
• 13. Subjects who were receiving systemic steroids prior to screening and determined by the investigator to require long-term systemic steroid use during treatment (other than inhalation or topical use); And subjects who were treated with systemic steroids (except for inhalation or topical use) within 72 h prior to cell infusion;
• 14. A history of severe allergies or allergies;
• 15. Subjects requiring anticoagulant therapy;
• 16. Women who are pregnant or breast-feeding, or have a pregnancy plan within six months (for both men and women);
• 17. Researchers believe that there are other reasons not to include patients in the treatment.